The Uromigos Episodes by Conference
ASCO
Silke Gillessen joins Tom and Brian, who give their opinion on new data presented at the conference.
David McDermott discusses the adjuvant vs neoadjuvant trial and its wider implications for the genitourinary oncology field.
Advertisement
ASCO GU
Reviewing the top presentations from ASCO GU 2024, including the phase III GETUG-AFU-18 study, CONTACT-02, and more.
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
EAU
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
ESMO
Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024.
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
IKCS
Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.
The Uromigos: Live & Unplugged
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.